Spots Global Cancer Trial Database for gastroesophageal junction
Every month we try and update this database with for gastroesophageal junction cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers | NCT00848783 | Gastric Cancer Gastric Adenoca... Esophageal Canc... | Irinotecan Cisplatin Surgery Floxuridine Capecitabine | 18 Years - | NYU Langone Health | |
| Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial | NCT01512589 | Esophageal Canc... | Proton Beam The... Intensity Modul... Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas | NCT01253525 | Adenocarcinoma | Ramucirumab (IM... Paclitaxel | 20 Years - | Eli Lilly and Company | |
| Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations | NCT05019794 | Gastric Cancer Gastroesophagea... Solid Tumor | Infigratinib | 18 Years - 75 Years | LianBio LLC | |
| Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach | NCT01472029 | Adenocarcinoma ... Adenocarcinoma ... | 5-FU, leucovori... Post-operative ... | 18 Years - | AIO-Studien-gGmbH | |
| Trimodality Management of T1b Esophageal Cancers | NCT01217060 | Esophageal Canc... | Docetaxel 5-FU Radiotherapy Esophagectomy Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) | NCT00525785 | Stomach Cancer Gastric Cancer | 5-Fluorouracil Folinic Acid Oxaliplatin Radiotherapy Surgery | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | NCT05411133 | Gastrointestina... Cholangiocarcin... Liver Cancer Colorectal Aden... Pancreatic Canc... Gastric Cancer Esophageal Aden... Gastroesophagea... | Cabotamig (ARB2... | 18 Years - | Arbele Limited | |
| Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma | NCT05067842 | Adenocarcinoma ... | Circulating tum... | 18 Years - 80 Years | Medical College of Wisconsin | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | NCT00813072 | Stomach Neoplas... Esophageal Neop... | PEP02 irinotecan docetaxel | 18 Years - | PharmaEngine | |
| KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer | NCT02205463 | Esophageal Canc... Stomach Cancer | KD019 | 18 Years - | NYU Langone Health | |
| Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas | NCT01253525 | Adenocarcinoma | Ramucirumab (IM... Paclitaxel | 20 Years - | Eli Lilly and Company | |
| An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | NCT03704077 | Gastric Cancer Cancer of the S... Stomach Cancer Gastroesophagea... | Relatlimab + Ni... Nivolumab Paclitaxel Ramucirumab | 18 Years - | Bristol-Myers Squibb | |
| APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | NCT03165994 | Esophageal Canc... GastroEsophagea... | APX005M Radiation Thera... Paclitaxel Carboplatin Surgical resect... | 18 Years - | Apexigen America, Inc. | |
| Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment | NCT01262482 | Advanced or Met... | Oxaliplatin Sorafenib | 18 Years - | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma | NCT00515411 | Gastroesophagea... Gastric Cancer | Docetaxel, Leuc... Docetaxel, Cisp... Docetaxel, Leuk... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer | NCT02205463 | Esophageal Canc... Stomach Cancer | KD019 | 18 Years - | NYU Langone Health | |
| Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma | NCT00515411 | Gastroesophagea... Gastric Cancer | Docetaxel, Leuc... Docetaxel, Cisp... Docetaxel, Leuk... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors | NCT04460456 | HER2 Positive S... | SBT6050 pembrolizumab Cemiplimab | 18 Years - | Silverback Therapeutics | |
| Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | NCT04681248 | Esophageal Neop... Adenocarcinoma ... GastroEsophagea... Squamous Cell C... Gastric Adenoca... Endometrial Can... Uterine Cancer Ovarian Cancer Carcinosarcoma Gastric Cancer | DKN-01 | 18 Years - | Leap Therapeutics, Inc. | |
| Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer | NCT02415101 | Cancer of the E... | Resective surge... | 18 Years - 80 Years | Karolinska University Hospital | |
| Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma | NCT05067842 | Adenocarcinoma ... | Circulating tum... | 18 Years - 80 Years | Medical College of Wisconsin | |
| Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer | NCT02415101 | Cancer of the E... | Resective surge... | 18 Years - 80 Years | Karolinska University Hospital | |
| Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) | NCT00525785 | Stomach Cancer Gastric Cancer | 5-Fluorouracil Folinic Acid Oxaliplatin Radiotherapy Surgery | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach | NCT01472029 | Adenocarcinoma ... Adenocarcinoma ... | 5-FU, leucovori... Post-operative ... | 18 Years - | AIO-Studien-gGmbH | |
| Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction | NCT00080002 | Cancer of Stoma... Gastroesophagea... | Pegamotecan | 18 Years - | Enzon Pharmaceuticals, Inc. | |
| Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers | NCT00848783 | Gastric Cancer Gastric Adenoca... Esophageal Canc... | Irinotecan Cisplatin Surgery Floxuridine Capecitabine | 18 Years - | NYU Langone Health | |
| Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment | NCT02274012 | HER-2 Positive ... Gastrooesophage... Esophageal Canc... | Afatinib Paclitaxel | 18 Years - | Columbia University | |
| Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma | NCT00525915 | Esophageal Canc... Gastroesophagea... | 5-Fluorouracil Oxaliplatin Radiation Thera... Surgery | 18 Years - 76 Years | M.D. Anderson Cancer Center | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer | NCT02415101 | Cancer of the E... | Resective surge... | 18 Years - 80 Years | Karolinska University Hospital | |
| Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | NCT05411133 | Gastrointestina... Cholangiocarcin... Liver Cancer Colorectal Aden... Pancreatic Canc... Gastric Cancer Esophageal Aden... Gastroesophagea... | Cabotamig (ARB2... | 18 Years - | Arbele Limited | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial | NCT01512589 | Esophageal Canc... | Proton Beam The... Intensity Modul... Questionnaires | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
